CRISPR-Based Diagnostics: A Potential Tool to Address the Diagnostic Challenges of Tuberculosis

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, which infects more than 23% of the world’s population. With the emergence of drug-resistant TB (DR-TB) and latent TB infection (LTBI), rapid diagnosis of DR-TB and LTBI has become a challenge for the prevention and control of TB. Herein, we highlight these challenges and discuss emerging clustered regularly interspaced short palindromic repeats (CRISPR)-based diagnostics in TB detection. Currently, the clinical diagnosis of M. tuberculosis infection mainly depends on pathogenic and molecular biological methods, including sputum smear, sputum culture, and Xpert. Although CRISPR-based diagnostics have not been applied to the clinical diagnosis of TB, they have shown exciting preponderances in TB diagnosis compared with traditional methods, including higher sensitivity, less sample input, and shorter turnaround time. CRISPR-based diagnostics represent a potential tool to address the challenges and natural weaknesses associated with traditional TB diagnosis methods. Based on the currently available data, we suggest that future CRISPR-based TB diagnostics should be developed in the direction of automation, modularization, diversification, and intelligence. By combining the CRISPR platform with various systems, such as microfluidic chips, droplet microfluidics, electrochemical techniques, and optical systems, the specificity and sensitivity of TB diagnosis may be revolutionized.

[1]  F. He,et al.  Development of an MSPQC Nucleic Acid Sensor Based on CRISPR/Cas9 for the Detection of Mycobacterium tuberculosis. , 2022, Analytical chemistry.

[2]  H. Deng,et al.  A Highly Sensitive and Specific Detection Method for Mycobacterium tuberculosis Fluoroquinolone Resistance Mutations Utilizing the CRISPR-Cas13a System , 2022, Frontiers in Microbiology.

[3]  Irene N Njuguna,et al.  CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study , 2022, The Lancet. Microbe.

[4]  Yanju Chen,et al.  Advances in amplification-free detection of nucleic acid: CRISPR/Cas system as a powerful tool. , 2022, Analytical biochemistry.

[5]  M. Eisenstein Seven technologies to watch in 2022 , 2022, Nature.

[6]  Fei Huang,et al.  Global control of tuberculosis: current status and future prospects , 2022 .

[7]  Xingxu Huang,et al.  A Recombinase Polymerase Amplification-Coupled Cas12a Mutant-Based Module for Efficient Detection of Streptomycin-Resistant Mutations in Mycobacterium tuberculosis , 2022, Frontiers in Microbiology.

[8]  Xiong Zhu,et al.  LAMP-CRISPR-Cas12-based diagnostic platform for detection of Mycobacterium tuberculosis complex using real-time fluorescence or lateral flow test , 2021, Microchimica Acta.

[9]  Shiyuan Li,et al.  TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosis. , 2021, The Journal of infection.

[10]  A. Kostyusheva,et al.  CRISPR-Cas systems for diagnosing infectious diseases , 2020, Methods.

[11]  Xiaolong Liu,et al.  An isothermal method for sensitive detection of Mycobacterium tuberculosis complex using CRISPR/Cas12a cis- and trans-cleavage. , 2020, The Journal of molecular diagnostics : JMD.

[12]  Ashutosh Kumar Singh,et al.  Diagnostic performance of non-invasive, stool-based molecular assays in patients with paucibacillary tuberculosis , 2020, Scientific Reports.

[13]  Teng Xu,et al.  CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis , 2019, Emerging microbes & infections.

[14]  Alimuddin Zumla,et al.  Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. , 2018, The Lancet. Infectious diseases.

[15]  Hayden C. Metsky,et al.  Field-deployable viral diagnostics using CRISPR-Cas13 , 2018, Science.

[16]  Jennifer A. Doudna,et al.  CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity , 2018, Science.

[17]  Aviv Regev,et al.  Nucleic acid detection with CRISPR-Cas13a/C2c2 , 2017, Science.

[18]  Peter J Dodd,et al.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling , 2016, PLoS medicine.